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Abstract
In this study, a full factorial approach was employed to investigate the effects of poly(ethylene
glycol) (PEG) molecular weight (10,000 vs. 35,000 nominal molecular weight), crosslinker-to-
macromer carbon-carbon double bond ratio (40 vs. 60), crosslinker type (PEG-diacrylate
(PEGDA) vs. N,N′–methylene bisacrylamide (MB)), crosslinking extent of incorporated gelatin
microparticles (low vs. high), and incubation medium composition (with or without collagenase)
on the swelling and degradation characteristics of oligo(poly(ethylene glycol) fumarate) (OPF)
hydrogel composites as indicated by the swelling ratio and the % mass remaining, respectively.
Each factor consisted of two levels, which were selected based on previous in vitro and in vivo
studies utilizing these hydrogels for various tissue engineering applications. Fractional factorial
analyses of the main effects indicated that the mean swelling ratio and the mean % mass
remaining of OPF composite hydrogels were significantly affected by every factor. In particular,
increasing the PEG chain MW of OPF macromers significantly increased the mean swelling ratio
and decreased the mean % mass remaining by 5.7±0.3 and 17.2±0.6 %, respectively. However,
changing the crosslinker from MB to PEGDA reduced the mean swelling ratio and increased the
mean % mass remaining of OPF composite hydrogels by 4.9±0.2 and 9.4±0.9 %, respectively.
Additionally, it was found that the swelling characteristics of hydrogels fabricated with higher
PEG chain MW or with MB were more sensitive to increases in DBR. Collectively, the main and
cross effects observed between factors enables informed tuning of the swelling and degradation
properties of OPF-based hydrogels for various tissue engineering applications.
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Poly(ethylene glycol) (PEG)-based hydrogels are currently being investigated for a myriad
of biomedical applications, including drug delivery, surface modifications, diagnostic
devices, and tissue engineering due to their appeal as a hydrophilic and cytocompatible
biomaterial as well as the range of physicochemical properties that can be achieved to meet
the needs of the application 1. These materials are of particular interest for tissue engineering
applications because of their ability to mimic the extracellular matrix of tissues and direct
the growth of neo-tissue within a three-dimensional architecture 2,3. By varying parameters
such as network morphology, crosslinking density, and polymer composition, PEG-based
hydrogels can be easily tailored to meet the requirements for regeneration of a multitude of
tissue types 4.
Many tissue engineering strategies involving hydrogel scaffolds have taken advantage of
their high water content to deliver a variety of bioactive molecules and encapsulated cells to
promote tissue regeneration 2,3. The high equilibrium swelling allows increased diffusion of
nutrients in and cellular waste and bioactive molecules out of the hydrogels. Additionally,
the extent of hydrogel swelling has been shown to be a critical factor in directing cell
behavior and tuning the release kinetics of bioactive molecules 5–7. Also, just as important is
the role of hydrogel degradation in affecting cell fate and facilitating neo-tissue
formation 8–10. Indeed, finding the appropriate balance among different parameters that can
affect swelling and degradation of PEG-based hydrogels remains a challenge for targeted
tissue regeneration.
The present study examines the use of oligo(poly(ethylene glycol) fumarate) (OPF)-based
hydrogels that have shown great tunability for a variety of tissue engineering
applications 11–19. OPF is a water-soluble synthetic macromer with alternating PEG chains
and fumarate groups that allow for crosslinking and degradation into products readily
cleared by the body 20. It has been previously shown that modulating the PEG chain
length 15 and changing the crosslinker-to-OPF carbon-carbon double bond ratio (DBR) 12
can affect the hydrogel mesh size and crosslinking density of the hydrogel. In addition,
gelatin microparticles (GMP) encapsulated within the gel can provide digestible porogens to
expedite OPF hydrogel composite degradation 11,21. However, possible interactions between
various factors and their combined effects on key hydrogel properties remain to be
elucidated through a systematic investigation.
Accordingly, the objective of this study is to investigate the effect of hydrogel construction
parameters on the swelling ratio and degradation of OPF hydrogel composites and to
evaluate the statistical interactions between various parameters in a full factorial design.
Five hydrogel construction parameters are studied: PEG chain molecular weight (MW),
DBR, type of crosslinker, crosslinking density of GMPs, and the incubation medium
composition.
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For the synthesis of OPF, PEG of 10,000 g/moL and 35,000 g/moL nominal MW, calcium
hydride, ammonium persulfate (APS), ethyl acetate, triethylamine, and N,N,N′,N′ –
tetramethylethylenediamine (TEMED) were purchased from Sigma Aldrich (St. Louis,
MO). Dichloromethane and ethyl ether were obtained from EMD Millipore Chemicals
(Billerica, MA). Anhydrous methylene chloride was obtained by distillation after the reflux
of dichloromethane for 2 hrs in the presence of calcium hydride. Fumaryl chloride was
purchased from Fisher Scientific and distilled before use. Toluene was also purchased from
Fisher Scientific (Pittsburgh, PA). All other solvents were of reagent grade and used as
received.
For the fabrication of gelatin microparticles (GMP), acidic gelatin with an isoelectric point
of 5.0 was obtained from Nitta Gelatin INC (Osaka, Japan). Tween 80, glutaraldehyde, Span
80, and glycine were purchased from Sigma Aldrich. For the fabrication of OPF/GMP
composite hydrogels, poly(ethylene glycol)-diacrylate (PEGDA) (nominal MW of 3,400)
was purchased from Laysan (Arab, AL). N,N′–methylene bisacrylamide (MB) was
purchased from Sigma Aldrich.
OPF Synthesis and Characterization
OPF of two different formulations was synthesized using PEG of two different nominal MW
(10,000 g/moL and 35,000 g/moL) according to established procedures 13,22 and will be
referred to as OPF 10K and OPF 35K, respectively. Briefly, PEG (~50 g) was first dried via
azeotropic distillation in 200 mL of toluene and then dissolved in ~300 mL of anhydrous
methylene chloride for the synthesis reaction. After the dissolution of PEG, the reaction
vessel was stirred in an ice bath and maintained under nitrogen, while distilled fumaryl
chloride (0.9 mol fumaryl chloride/1 mol PEG) and triethylamine (2 mol triethylamine/1
mol fumaryl chloride) were added dropwise. Upon completing the addition of the reagents,
the reaction flask was removed from the ice bath and stirred for an additional 48 hrs at room
temperature (25 °C). OPF was then purified by rotary evaporation for the removal of
methylene chloride, dissolved in ethyl acetate, vacuum-filtered to remove salt precipitates
(from the reaction of chloride with triethylamine), and washed with ethyl ether. The PEG
(PEG 10K: Mn of 8880±90 and Mw of 12110±40; PEG 35K: Mn of 40650±1140 and Mw of
54830±1560) as well as the resulting OPF were characterized via gel permeation
chromatography where PEG standards were used to construct a calibration curve (OPF 10K:
Mn of 24880±1680 and Mw of 152490±5800; OPF 35K: Mn of 44880±840 and Mw of
92120±8860). The OPF was stored at −20 °C until use.
Gelatin Microparticle Fabrication
GMPs were fabricated using acidic gelatin with an isoelectric point of 5.0 following
previously established procedures 11. Briefly, 5 g of gelatin was dissolved in 45 mL of
distilled, deionized water (ddH20) at 60 °C for ~20 minutes. The resulting aqueous gelatin
solution was added dropwise to 250 mL of olive oil containing 0.5 wt.% Span 80 during
mixing at 500 rpm for the formation of microspheres in the water/oil emulsion. The
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emulsion was then placed in an ice/water bath with continued stirring for 30 minutes, after
which 100 mL of chilled acetone was added. After 1 hr, gelatin microspheres were collected
from the emulsion via filtration and washing with acetone for the removal of residual olive
oil. Collected gelatin microspheres were then crosslinked in 0.1 wt.% solution of Tween 80
in ddH20 containing either 10 mM (10 mM GMP) or 40 mM glutaraldehyde (40 mM GMP)
for 20 hrs in an ice/water bath with stirring at 500 rpm. Glycine was then added to the
reaction flask to a concentration of 25 mM and incubated for 1 hr to terminate the
crosslinking reaction by blocking the residual aldehyde groups of unreacted glutaraldehyde.
The crosslinked GMPs were vacuum-filtered, washed with ddH20, and lyophilized
overnight. After lyophilization, GMPs with a diameter of 50–100 μm were selected by
sieving and then stored at −20 °C until use.
Experimental Design
A full factorial design was utilized to investigate the effects of (1) PEG chain MW, (2)
DBR, (3) crosslinker type, (4) crosslinking density of GMPs, and (5) incubation medium
composition on the degradation characteristics and profiles of OPF composite hydrogels
(Table 1). During fabrication of the OPF composite hydrogels, it was found that
formulations containing OPF 35k and MB as a crosslinker could not be formed under
similar conditions for other formulations. Thus, the full factorial design could not be
completed as planned. Accordingly, two 24 fractional factorial studies were designed, as
outlined in Table 2, to fully investigate the effects of all five aforementioned parameters.
Each factor consisted of two levels, which were chosen based on previous in vitro and in
vivo studies utilizing these hydrogels for various orthopedic applications 11,20,23–25. 10k and
35k PEG chain MWs were seen to facilitate the greatest chondrogenic differentiation among
mesenchymal stem cells encapsulated in OPF-based hydrogels over smaller PEG chain
MWs 15. Additionally, the DBR level of 60 was based on OPF:PEGDA weight ratios
previously used 7,18,25 and the DBR level of 40 represents the threshold beyond which gels
containing OPF 35k and PEGDA could not be formed. All formulations in Study 1 used
PEGDA as the crosslinker and all formulations in Study 2 used 10k as the PEG MW for
OPF hydrogel fabrication.
Composite Fabrication
OPF composite hydrogels were fabricated by encapsulating either 10 mM or 40 mM GMPs
in OPF hydrogels according to previously established methods 26,27. Varying amounts of
OPF macromer were combined with varying amounts of PEGDA or MB to give two
different levels of DBR as seen in Supplementary Table 1. DBR was defined as the ratio of
the total number of carbon-carbon double bonds in the crosslinker (PEGDA or MB) over the
total number of carbon-carbon double bonds in OPF. The number of carbon-carbon double
bonds in OPF was estimated by the following formula:  of a
fumarate unit (i.e., 72 g/mol) × x = Mn of OPF, where x is the average number of carbon-
carbon double bonds in an OPF macromer. To outline the general fabrication procedure, the
prescribed amounts of OPF and either PEGDA or MB were dissolved in 468 μL of
phosphate-buffered saline (PBS) and thoroughly mixed with 22 mg of GMPs that were
previously swollen overnight with 110 μL of PBS. Equal parts (48.6 μL) of the thermal
radical initiators APS (0.3 M) and TEMED (0.3 M) were then added to initiate the
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crosslinking reaction. After mixing, the polymeric suspension was quickly injected into a
cylindrical Teflon mold (6 mm in diameter and 2 mm in thickness) and further incubated at
37 °C for 10 minutes to achieve crosslinking.
OPF Swelling and Degradation Study
For the swelling and the degradation studies, OPF composite hydrogels were placed in either
3 mL of PBS or collagenase-conditioned PBS (Col-PBS; 400 ng collagenase 1A per mL
PBS) in a 12-well plate and incubated at 37 °C for 28 days under shaking at 70 rpm. The
culture medium was replaced every 3 days. At days 1, 4, 7, 14, 21, and 28, composite
hydrogels (n=4) dedicated to each time point were retrieved to determine swelling ratio and
% mass remaining using the following equations:  and
 where Wi, Ws, and Wd are the weight of the dried
composite immediately after fabrication prior to swelling, the weight of the composite after
swelling at each time point, and the weight of the dried composite after swelling at each time
point, respectively.
Statistical Analysis
Data for the measured properties were reported as mean ± standard deviation for samples
(n=4) at each time point. Differences in the degradation characteristics between the various
formulations were determined via one-way ANOVA followed by Tukey’s HSD post hoc
analysis (p<0.05). Main and interaction effects were analyzed using a linear regression
analysis methodology via the SAS JMP Pro 10 software according to previously established
methods 28,29.
RESULTS
Swelling of OPF Composite Hydrogels
Equilibrium swelling ratios were first compared between groups with the same incubation
medium composition as outlined in Tables 3 and 4. In standard PBS, all formulations
containing 10 mM GMPs maintained generally constant swelling ratios within each
respective group over 28 days (Supplementary Figure 1a). Composites from formulations
35kDA40:10 and 10kMB40:10 both exhibited the highest swelling ratios up until day 28.
Composites fabricated with OPF 10K macromers and PEGDA as the crosslinker
(10kDA60:10 and 10kDA40:10) showed the lowest mean swelling ratios over time. Among
formulations containing 40 mM GMPs (Supplementary Figure 1b), 35kDA40:40 and
10kMB40:40 had the highest swelling ratios at the measured time points after day 1. Despite
having similar mean swelling ratios, which refer to overall values over time, of 17.2±0.4 for
35kDA40:40 and 17.9±0.6 for 10kMB40:40, composites from 10kMB40:40 swelled more
than those from 35kDA40:40 at each time point measured after day 14. The mean swelling
ratios of formulations 35kDA60:40 (13.6±0.3) and 10kMB60:40 (14.1±0.4), while lower
than those of their lower DBR counterparts, were greater than the mean swelling ratios of
10kDA60:40 (5.6±0.2) and 10kDA40:40 (6.0±0.2) as shown in Table 3.
In Figure 1a, formulation 35kDA40:10, which maintained the highest mean swelling ratio of
26.7±1.5 in col-PBS over 28 days, exhibited greater increases in swelling following day 4 in
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the presence of collagenase as compared to in PBS alone. As outlined in Table 3,
formulations 35kDA60:10 and 10kMB40:10 displayed the next highest swelling capacities
with mean swelling ratios of 18.1±0.8 and 19.2±0.6, respectively. Indeed, formulations
10kDA60:10 and 10kDA40:10, both of which had similar respective mean swelling ratios of
6.4±0.2 and 6.9±0.2, displayed the lowest swelling ratios at all time points when compared
to other formulations. For the formulations containing 40 mM GMPs (Figure 1b), the same
differences observed between swelling profiles of the respective experimental groups in
standard PBS were also observed in col-PBS.
Degradation of OPF Composite Hydrogels
In congruence with the hydrogel swelling ratios, the % mass remaining profiles of the
various experimental groups were first compared within the same incubation medium
composition in order to evaluate differences between formulations. In standard PBS,
formulations with OPF 35K (35kDA60:10 and 35kDA40:10) had the lowest mean % mass
remaining, which refer to overall values over time, and thereby the greatest overall polymer
loss over 28 days (Supplementary Figure 1c). As shown in Table 4, 10kDA60:10 (89.3±1.3
%) and 10kDA40:10 (82.8±1.4 %) maintained the highest mean % mass remaining amongst
formulations containing 10 mM GMPs. For the 40 mM GMP containing groups, similar
differences in mean % mass remaining between corresponding formulations were also
observed (Supplementary Figure 1d). For example, all formulations with OPF 10K and
PEGDA displayed the least polymer loss overall regardless of the GMP crosslinking extent
(Table 4). In standard PBS, the amount of polymer loss for all formulations (containing 10
mM GMPs or 40 mM GMPs) stabilized after day 7.
In col-PBS, the overall polymer loss amid the 10 mM GMP composite formulations was
highest amongst formulations containing OPF 35K macromers. For instance, 35kDA60:10
and 35kDA40:10 had mean mass remaining percentages of 43.1±2.3 % and 37.4±2.7 %,
respectively, which were at least 12% lower than other formulations (Table 4). With the
exception of the formulations 10kDA60:10 and 10kDA40:10, which had the lowest amounts
of overall polymer loss, all groups exhibited increasing polymer loss under enzymatic
conditions until stabilization after day 14 (Figure 1c). Although the differences in mean %
mass remaining between 10 mM GMP containing formulations were also observed between
the 40 mM GMP containing groups, the latter maintained higher mean mass remaining
percentages than their 10 mM GMP containing counterparts (Figure 1d).
In order to formally investigate the main effects of the construction parameters outlined in
Table 1 and their various interactions on the swelling and degradation of OPF composite
hydrogels, two 24 fractional factorial analyses were performed as detailed in Table 2. In
Figures 2, 3, 4, and 5, the magnitude of the changes associated with the main effects and
interactions are shown with standard error bars relative to the zero line, which is
representative of the overall population mean at each effect. Main effects and interactions
were considered significant (p<0.05) if their standard error did not cross the zero line.
Lam et al. Page 6













Fractional Factorial Analysis of Study 1
Study 1 investigated four main factors: GMP crosslinking extent, PEG chain MW,
incubation medium composition, and DBR, while keeping the crosslinker type (PEGDA)
constant. Main effects analysis of the OPF composite formulations over 28 days indicated
that all four factors had an effect on the swelling ratio (Figure 2a). When OPF composites
were fabricated with GMPs of the higher crosslinking density (40 mM) and the higher DBR
(60), the mean swelling ratio decreased by an average of 0.7±0.3 and 1.5±0.3, respectively.
Similarly, changing the incubation medium composition from col-PBS to standard PBS
caused a decrease in the mean swelling ratio by an average of 1.2±0.3. An increase in the
PEG chain MW from 10K to 35K resulted in a significant increase in the mean swelling
ratio by an average of 5.7±0.3. Through the analysis of the main effects at each time point, it
was observed that the OPF macromer MW and the DBR significantly affected the swelling
ratio at all times (Supplementary Figure 2a). Although the incubation medium did not have
an immediate effect on the swelling ratio, the presence of collagenase caused an increase in
the swelling from day 4 onward. While increasing the GMP crosslinking extent (10 mM to
40 mM) also did not have an immediate effect on the swelling ratio, it significantly
decreased the swelling ratio from day 4 until day 21.
The mean % mass remaining was also affected by all four factors as indicated by main
effects analysis (Fig 3b). Particularly, an increase in the GMP crosslinking extent and the
DBR resulted in an increase in the mean % mass remaining by an average of 2.2±0.6 % and
2.0±0.6 %, respectively. Removal of the enzymatic incubation condition also caused an
increase in the mean % mass remaining by an average of 4.0±0.6 %. However, an increase
in the PEG chain MW yielded a significant decrease in the mean % mass remaining by an
average of 17.2±0.6 %. An analysis of the main effects at each time point showed that PEG
chain MW and incubation medium composition had an effect on mean % mass remaining at
all times (Supplementary Figure 2b). GMP crosslinking extent and DBR also had an effect
on the mean % mass remaining at all measured time points except for day 1. An evaluation
of the interactions between factors on the mean swelling ratio revealed an interdependence
of factors upon one another in the form of several 2-factor and 3-factor interactions. In
particular, significant 2-factor interactions (where A*B denotes a cross effect between factor
A and factor B) included GMP*MW, GMP*Medium, MW*Medium, MW*DBR, and
Medium*DBR, while 3-factor interactions included GMP*MW*Medium and
MW*Medium*DBR (data not shown). For the mean % mass remaining, significant
interactions only included GMP*MW and GMP*DBR. The cross effects between PEG
chain MW, DBR, and the incubation medium composition, which had the largest impact on
swelling, are further illustrated in Figure 3.
Fractional Factorial Analysis of Study 2
Main effects analysis of the formulations from Study 2 over 28 days, which corroborated the
effects of incubation medium composition and DBR on swelling, also demonstrated that the
crosslinker type significantly impacted the mean swelling ratio (Figure 4a). Employing
PEGDA as the crosslinker instead of MB caused a significant decrease in the mean swelling
ratio by an average of 4.9±0.2. Amongst formulations incorporating only OPF 10K
macromers, increasing the DBR resulted in a decrease in the mean swelling ratio by an
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average of 1.2±0.2. However, GMP crosslinking extent was not a significant factor affecting
the mean swelling ratio of these formulations. Changing the GMP crosslinking extent, the
incubation medium composition, and the DBR from the respective level 1 to level 2 values
raised the mean % mass remaining by an average of 1.0±0.9 %, 2.8±0.9 %, and 2.7±0.9 %,
respectively (Figure 4b). Most notably, changing the crosslinker type from MB to PEGDA
increased the mean % mass remaining by an average of 9.4±0.9 %. An analysis of the main
effects on mean swelling ratio over time showed that the crosslinker type and the DBR had
an effect at all times, while the GMP crosslinking extent and the incubation medium
composition both had an effect at day 28 (Supplementary Figure 3a). Similar to the main
effects on the mean swelling ratio, the crosslinker type and DBR significantly affected the
mean % mass remaining at all measured time points (Supplementary Figure 3b). However,
GMP crosslinking extent and the incubation medium composition only had effects on the
mean % mass remaining at select time points and did not display any noticeable effects
pattern. From the evaluation of the interactions present in Study 2, notable cross effects
between factors included only three 2-factor interactions that affected the mean swelling
ratio: GMP*Crosslinker, Crosslinker*DBR, and Medium*DBR (data not shown). The
interaction effects between crosslinker and DBR, which proved to have the greatest impact
on swelling, are further described in Figure 5.
DISCUSSION
This study utilized a full factorial design with fractional factorial analyses to investigate the
effects of PEG chain MW, DBR, crosslinker type, GMP crosslinking extent, and the
incubation medium composition on the swelling and degradation characteristics of OPF
composite hydrogels. With each factor comprising two-levels, it was hypothesized that the
swelling and degradation characteristics of OPF composite hydrogels could be precisely
controlled by individually or collectively modulating the levels of the aforementioned
parameters. Furthermore, it was envisioned that the use of a factorial design would allow for
the evaluation of how each individual factor and their various interactions with each other
would affect the swelling and degradation of these composites. Indeed, the fractional
factorial analyses of the main effects showed that the mean swelling ratio and the mean %
mass remaining of OPF composite hydrogels were significantly impacted by every
parameter investigated. Additionally, an analysis of the interactions between parameters
yielded important insights to guide the tuning of the swelling and degradation properties of
OPF-based hydrogels.
Previous studies have briefly evaluated the individual effects of PEG chain MW 15, GMP
crosslinking extent 11, and DBR 20 on the degradation of OPF composite hydrogels.
Additionally, previous research conducted by our laboratory has investigated the effect of
PEG chain MW on the swelling and mechanical properties of OPF-based hydrogels and
found that with an increase in PEG molecular weight and hence, the hydrogel swelling, the
tensile strength of the OPF-based hydrogels decreased 16. However, the combined effects of
these factors, along with the crosslinker type and the incubation medium composition, as
well as their various interactions on swelling and degradation had not been investigated.
While the mechanical properties of hydrogel scaffolds are important, particularly for
dynamic tissues, the main focus of the current study is on how different hydrogel
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construction parameters affect swelling and degradation for applications in cell and drug
delivery. Hence, a factorial experiment combining all of these factors was designed. Out of
the composite formulations that were generated from this factorial design, all formulations
containing OPF 35K macromers and the crosslinker MB failed to yield any viable hydrogels
due to a low level of crosslinking. This could be attributed to the limited mobility of the
second double bond of the MB crosslinking agent after the first one has reacted during the
crosslinking reaction with the larger sized OPF 35K macromers. However, crosslinking with
PEG-DA is possible because the mobility of the second double bond is greater due to the
presence of a PEG spacer, which is not the case for MB. This could also be due to the
reduced number of fumarate groups (which carry the unsaturated carbon-carbon double
bonds) per OPF macromer for OPF 35K when compared to OPF 10K as a result of the steric
hindrance of higher MW PEG molecules inhibiting the addition of fumarate groups to the
ends of the PEG molecules during synthesis 22. Accordingly, two 24 fractional factorial
analyses were performed with the remaining composite formulations in order to fully
evaluate the main and interaction effects of all construction parameters on swelling and
degradation.
First, the mean swelling ratios between groups within the same incubation medium
composition were compared. Although composites fabricated with OPF 35K macromers
were expected to achieve the highest swelling ratios, this was not the case as formulations
35kDA40:10, 10kMB40:10, 35kDA40:40, and 10kMB40:40 exhibited similarly high mean
swelling ratios over 28 days. Additionally, 10kMB60:10, 10kMB60:40, 10kMB40:10, and
10kMB40:40 achieved swelling ratios similar to or greater than that of 35kDA60:10 or
35kDA60:40. From the swelling data alone, this result could be mainly due to the
crosslinker type. Assuming that all OPF macromers were incorporated during crosslinking
to form a polymer network, the theoretical swelling capacity of the resulting hydrogel would
be directly related to the size of the PEG chain component, as larger PEG components equal
greater swelling30. Indeed, 35kDA60:10/35kDA60:40 and 35kDA40:10/35kDA40:40
exhibited greater swelling ratios than 10kDA60:10/10kDA60:40 and
10kDA40:10/10kDA40:40 at all measured times. However, a comparison of
10kDA60:10/10kDA60:40 and 10kDA40:10/10kDA40:40 with 10kMB60:10/10kMB60:40
and 10kMB40:10/10kMB40:40 indicated that formulations containing MB swelled more
than the corresponding PEGDA-containing formulations despite MB being the smaller
crosslinker (154.2 nominal MW compared to 3,400 nominal MW for PEGDA). This
phenomenon could potentially be explained by the relatively higher reactivity of acrylates
(PEGDA) or amides (MB) when compared to the carbon-carbon double bonds of the
fumarate groups along the OPF backbone 16,31,32. As a result, the acrylates from the
PEGDA crosslinkers may have more readily reacted with each other than with the fumarate
double bonds, leading to the formation of regional PEGDA networks within the overall OPF
macromolecular structure. This would act to not only lower the swelling capacity of the OPF
composites since the crosslinker PEGDA has a lower nominal MW compared to that of the
OPF macromers, but also to generally result in higher mass remaining percentages. Indeed,
main effects of increasing DBR on the swelling ratio and the % mass remaining as shown in
Figure 2 for Study 1 further indicate that the crosslinking density of such hydrogels is
directly correlated with the amount of acrylates present from the PEGDA crosslinker.
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Although similar reactions may have occurred amongst the amides of the MB crosslinkers,
the smaller size of MB would have less of an effect on the overall OPF network33 as
suggested by the lack of differences in mean mass remaining percentages between 10kMB
groups (incorporating GMPs of similar crosslinking extent) with changes in DBR (Tables 3
and 4).
While the size difference between MB and PEGDA may act to confound their differences in
reactivity as crosslinkers for OPF hydrogel systems, the selection of MB and PEGDA was
informed by previous studies from our laboratory and others investigating the efficacy of
materials utilizing these common crosslinkers for various in vitro and in vivo biomedical
applications 17,18,20,21,23,25. In particular, our laboratory has previously implanted OPF
hydrogels crosslinked with MB as controlled growth factor delivery vehicles for
osteochondral tissue repair 17,21. Although such acellular composites conferred some
therapeutic effects in vivo, the inclusion of stem cells to improve results may have been
difficult given reports of potential cytotoxicity with using MB 34,35. Hence, PEGDA was
employed as the crosslinker for the development of cell-laden OPF constructs. However,
when these constructs were used to deliver cells to an osteochondral defect site, fragments of
non-degraded hydrogel still present within the defect after 12 weeks obstructed tissue
repair 18. Given that OPF hydrogels crosslinked with MB displayed near complete
degradation in vivo by this time point 36, the presence of such non-degraded hydrogel
fragments was attributed to the use of PEGDA (via the formation of regional PEGDA
networks). As a result, both MB-crosslinked and PEGDA-crosslinked OPF systems were
compared in the present study in order to guide and optimize future strategies for combining
growth factor and cell delivery for in vivo tissue regeneration.
The absence of differences between corresponding formulations carrying either 10 mM
GMPs or 40 mM GMPs in standard PBS was expected given the lack of enzyme activity to
degrade GMPs in composite hydrogels. In the presence of collagenase, which mimics the
enzymatic conditions of an in vivo environment 26, various formulations including
35kDA60:10, 35kDA40:10, and 35kDA40:40 exhibited an increase in swelling capacity
when compared to their non-enzymatically treated counterparts. Indeed, encapsulated GMPs
swell and undergo enzymatic digestion over time, leading to the disruption of the OPF
network and the introduction of large pores into the bulk hydrogel that together enhance
hydrogel swelling 26. Additionally, higher swelling ratios were observed in 10 mM GMP
containing formulations in the collagenase medium condition when compared with
corresponding 40 mM GMP containing formulations, since GMPs of a higher crosslinking
extent can better resist enzymatic attack by collagenase. Previous results have shown that
the presence of collagenase failed to elicit enhanced swelling of OPF composites fabricated
with OPF 10K macromers that only contain 40 mM GMPs 26. However, in the current study,
the mean swelling ratio of 35kDA40:40 in col-PBS is significantly greater than its
corresponding value in standard PBS, suggesting an interaction between size of the OPF
macromer, the GMP crosslinking extent, and the enzyme.
Differences in the mass remaining percentages between formulations at day 1 are reflective
of the initial % sol fractions of each formulation. The % sol fraction, which is defined as 100
% minus the % mass remaining at day 1, reflects the amount of polymer that was not
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initially incorporated into the crosslinked network during composite fabrication. Although
formulations containing OPF 10K macromers and MB achieved similar swelling ratios with
formulations containing OPF 35K macromers and PEGDA, the latter displayed higher sol
fractions and lower subsequent polymer % mass remaining when compared to the former.
Indeed, given the increasing difficulty of attaching fumarate groups to the ends of larger
PEG molecules during OPF synthesis 13,22, hydrogels fabricated from OPF macromers with
larger PEG chains would contain many unreacted PEG molecules entangled within the
greater hydrogel network. Aside from the hydrolytic degradation of a less densely
crosslinked network, the release of these PEG molecules during swelling of the hydrogel
network and hydrolysis of degradable ester bonds could be the reason why formulations
with OPF 35K macromers exhibited greater polymer loss when compared to their 10K
counterparts.
For Study 1, the most significant factor affecting the mean swelling ratio and % mass
remaining was the PEG chain MW (Figure 2). Increasing the PEG chain MW caused a 2-
to-3-fold increase in the swelling capacity of the composite hydrogels. This was expected, as
larger PEG chains would allow for the formation of polymer networks with larger
theoretical mesh sizes. While not as influential as PEG chain MW, the DBR, GMP
crosslinking extent and the incubation medium composition also significantly impacted the
swelling properties of OPF composite hydrogels. Increasing the GMP crosslinking extent
decreased the overall swelling capacity of OPF composite hydrogels, most likely due to the
diminished swelling of more crosslinked GMPs 37. An increase in the DBR, which
correlates to an increased hydrogel crosslinking density, expectedly led to a decrease in
hydrogel swelling as well.
Interestingly, an analysis of the factor cross effects on swelling revealed that the effects of
DBR were more prominent for hydrogels formed from OPF 35K macromers. In standard
PBS, increasing the DBR from 40 to 60 decreased the mean swelling ratio of OPF 35K
composites by an average of 5.3 while the same increase in DBR for OPF 10K composites
decreased the mean swelling ratio by 0.5 (Figure 3). The interaction between these two
factors was even more apparent in enzymatic conditions. This is likely a consequence of the
difference in available fumarate groups for gelation between OPF 10K and OPF 35K
macromers. Compared to OPF 35K macromers, OPF 10K macromers have more fumarate
groups per macromer and thereby an increased probability of crosslinking during hydrogel
formation. In addition, with less fumarate groups per macromer, gelation of OPF 35K
hydrogels may be more dependent on the proportion of crosslinkers present in the reaction
mixture 33, which aligns with the Flory-Stockmayer theory for gelation. The presence of
collagenase predictably enhanced the interdependence of these two factors. Other
interactions involving the enzyme could also be explained by this same reason.
The Flory-Stockmayer theory would also explain the effects of DBR on the mass loss.
Increased branching during the gelation of OPF composites as a result of increased
crosslinker present in the reaction mixture yielded more crosslinked networks with
decreased overall hydrogel swelling capacity. The decrease in mass loss with increasing
DBR as seen in both fractional factorial studies further confirms this hypothesis. As
mentioned previously, the main effect of the PEG chain MW on the mean % mass remaining
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could be explained by the faster degradation of OPF 35K composites (due to the hydrolysis
of a more loosely crosslinked network) and/or the release of entangled unreacted PEG
molecules during swelling. The effect of GMP crosslinking extent could be explained by
two reasons. First, the decreased swelling of more crosslinked GMPs caused less hydrogel
network disruption and as a result, slowed the degradation of the composites. Second, more
crosslinked GMPs provided greater diffusional barriers against the release of OPF fragments
during degradation, thereby slowing overall polymer loss. Despite their individual effects,
the cross effects of PEG chain MW and DBR did not significantly influence the mean %
mass remaining and, hence the polymer loss. While there were several interactions between
factors, the cross effects on the mean % mass remaining were mainly peripheral.
For Study 2, the fractional factorial design was employed to primarily evaluate the impact of
crosslinker type and its interaction with other construction parameters on the swelling and
degradation of OPF composite hydrogels. As a result, the experimental groups involved in
this analysis only include composites fabricated using OPF 10K macromers. Among these
formulations, the most significant factor affecting the mean swelling ratio and % mass
remaining was the type of crosslinker used for gelation. Intriguingly, the utilization of the
larger crosslinker, PEGDA, instead of the smaller crosslinker, MB, led to a 20% to 50%
decrease in composite swelling capacity and a 30% to 60% decrease in composite
degradation. As mentioned previously, the use of PEGDA as the crosslinker, which has a
lower MW when compared to the OPF macromer, possibly resulted in the incorporation of
regional PEGDA networks within the overall hydrogel network that act to decrease the
overall hydrogel mesh size. With a decreased average mesh size, OPF composites
incorporating PEGDA would have decreased mean swelling ratios. Indeed, the cross effects
between crosslinker type and the DBR corroborates this explanation. The swelling
properties of OPF composite hydrogels fabricated with PEGDA were less sensitive to
changes in the DBR when compared to composites fabricated using MB. When coupled
with the limited swelling extent of the former, these results suggest that regional PEGDA
networks could potentially make up a portion of the overall polymer network of OPF
composite hydrogels. With regard to the other factors, the observed effects of GMP
crosslinking extent, DBR, and incubation medium composition on the swelling and
degradation of composites in Study 2 mainly corroborated those observed in Study 1.
The formulations evaluated in this study were based on various OPF systems that were
previously utilized as implants for in vivo tissue repair 17,18,27,36. As previously mentioned,
OPF systems incorporating MB were mainly used for growth factor delivery, while OPF
systems incorporating PEGDA were employed for the development of cell-laden constructs.
In cases where the beneficial effects of both growth factors and stem cells need to be
combined, the selection of the appropriate hydrogel formulation can be guided by the
findings of the current study. For instance, several of the formulations incorporating
PEGDA shared similar swelling and degradation properties with some formulations
incorporating MB, which may allow for the development of cell/growth factor-laden
hydrogel constructs that can swell and degrade as desired in vivo. Overall, the present study
demonstrated that the PEG chain MW and the crosslinker type had the greatest impact on
the swelling and degradation of OPF hydrogels. Additionally, the significant interaction
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effects between these two factors and the DBR showcased the high tunability that can be
achieved with such hydrogel systems, and have broad implications informing the design of
similar PEG-based hydrogel systems for cell encapsulation and growth factor delivery
applications.
CONCLUSIONS
In conclusion, the main and cross effects of (1) PEG chain MW, (2) DBR, (3) crosslinker
type, (4) GMP crosslinking extent, and (5) incubation medium composition on the swelling
and degradation characteristics of OPF composite hydrogels were investigated. While the
mean swelling ratio and mean % mass remaining of these hydrogels were impacted by every
factor, modifying the PEG chain MW and the crosslinker type produced the largest effects.
In particular, increasing the PEG chain MW from 10K to 35K increased both swelling and
polymer loss whereas using PEGDA instead of MB resulted in the opposite effect.
Moreover, it was found that interactions involving the DBR had the greatest cross effects on
swelling properties. The OPF hydrogels fabricated with PEGDA had lower increases in
swelling when the DBR was reduced when compared to hydrogels fabricated with MB.
Additionally, a cross effect was seen with 10mM GMP containing formulations in Col-PBS
exhibiting greater swelling than 40mM GMP containing formulations in the same condition.
Together, these results indicate that the swelling and degradation properties of OPF
hydrogels can be readily controlled via the collective modulation of key construction
parameters and underscore the versatility of these hydrogels as well as other PEG-based
hydrogels for drug and cell delivery in tissue engineering applications.
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Swelling ratio profiles of (a) 10 mM GMP or (b) 40 mM GMP containing OPF composite
hydrogels in col-PBS over 28 days (n=4). The mass remaining (%) profiles of corresponding
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(c) 10 mM GMP or (d) 40 mM GMP formulations in col-PBS over 28 days are also shown
(n=4). Error bars represent the standard deviation.
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The main effects of PEG chain MW, GMP crosslinking extent, DBR, and incubation
medium composition on the (a) swelling and (b) % mass remaining of OPF composite
hydrogels in Study 1. A positive value indicates an increasing effect caused by a change in
the corresponding parameter from level 1 to level 2. Error bars represent the standard error.
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Interaction effects between PEG chain MW, DBR, and the incubation medium composition
on the mean swelling ratio of OPF composite hydrogels in Study 1. A negative slope line
indicates that the swelling was decreased when the DBR was increased from 40 to 60.
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The main effects of crosslinker type, GMP crosslinking extent, DBR, and the incubation
medium composition on the (a) swelling and (b) % mass remaining of OPF composite
hydrogels in Study 2. A positive value indicates an increasing effect caused by a change in
the corresponding parameter from level 1 to level 2. Error bars represent the standard error.
Lam et al. Page 22














Interaction effects between the crosslinker type and the DBR on the mean swelling ratio of
OPF composite hydrogels in Study 2.
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Table 1
Two Levels of Five Parameters Tested in a Two-Level Full Factorial Design
Parameters Level 1 Level 2
PEG chain MW 10K 35K
DBR 40 60
Crosslinker Type MB PEGDA
GMP Crosslinking Extent 10 mM 40 mM
Incubation Medium Composition 400 ng/mL collagenase in PBS PBS
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Table 2
Levels for the Factors Tested in Studies 1 and 2 Following a Two-Level Fractional Factorial Design
Study 1 GMP Medium DBR PEG chain MW
Level 1 10 mM Col-PBS 40 10,000
Level 2 40 mM PBS 60 35,000
Study 2 GMP Medium DBR Crosslinker Type
Level 1 10 mM Col-PBS 40 MB
Level 2 40 mM PBS 60 PEGDA
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